Asset Details
Do you wish to reserve the book?
Reassessing target antigens for adoptive T-cell therapy
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Reassessing target antigens for adoptive T-cell therapy
Do you wish to request the book?
Reassessing target antigens for adoptive T-cell therapy
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Reassessing target antigens for adoptive T-cell therapy
2013
Overview
Adoptive T-cell therapy can target and kill widespread malignant cells thereby inducing durable clinical responses in melanoma and selected other malignances. However, many commonly targeted tumor antigens are also expressed by healthy tissues, and T cells do not distinguish between benign and malignant tissues if both express the target antigen. Autoimmune toxicity from T cell–mediated destruction of normal tissue has limited the development and adoption of this otherwise promising type of cancer therapy. A review of the unique biology of T-cell therapy and of recent clinical experience compels a reassessment of target antigens that traditionally have been viewed from the perspective of weaker immunotherapeutic modalities. It is important that target antigens chosen for adoptive T-cell therapy are expressed by tumors and not by essential healthy tissues. The risk of adverse autoimmune events can be further mitigated by generating antigen receptors using strategies that reduce the chance of cross-reactivity against epitopes in unintended targets. In general, a circumspect approach to target selection and thoughtful preclinical and clinical studies are pivotal to the ongoing advancement of these promising treatments.
Publisher
Nature Publishing Group UK,Nature Publishing Group
Subject
/ Animals
/ Antigens
/ Autoimmune Diseases - immunology
/ Biomedical Engineering/Biotechnology
/ Cancer
/ Cell- and Tissue-Based Therapy - adverse effects
/ Cell- and Tissue-Based Therapy - methods
/ Cross Reactions - immunology
/ Epitopes
/ Humans
/ Immunotherapy, Adoptive - adverse effects
/ Immunotherapy, Adoptive - methods
/ Melanoma
/ T cells
/ Testing
/ Therapy
/ Tissues
/ Toxicity
/ Tumors
